You searched for side effects - Page 70 of 311 - Medivizor
Navigation Menu

Does sotagliflozin reduce the risk of serious heart disease in patients with type 2 diabetes and kidney disease?

Does sotagliflozin reduce the risk of serious heart disease in patients with type 2 diabetes and kidney disease?

Posted by on Jan 4, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the use of sotagliflozin (Zynquista) in patients with poorly controlled type 2 diabetes (T2D) and chronic kidney disease (CKD). It found that patients taking sotagliflozin was associated with a lower risk of heart attack, stroke, or death.  Some background Patients with T2D and CKD are...

Read More

Dasatinib and blinatumomab for patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Dasatinib and blinatumomab for patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Posted by on Jan 4, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of dasatinib (Sprycel) and blinatumomab (Blincyto) as a first-line therapy in patients with Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL).  This study concluded that this treatment combination led to better response and survival in these...

Read More

Intensity-modulated radiation therapy with simultaneously integrated boost leads to shorter treatment time with similar outcomes as conventional radiotherapy after surgery for breast cancer

Intensity-modulated radiation therapy with simultaneously integrated boost leads to shorter treatment time with similar outcomes as conventional radiotherapy after surgery for breast cancer

Posted by on Jan 2, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effects of intensity-modulated radiation therapy (IMRT) with a simultaneously integrated boost (SIB) to conventional radiotherapy (CRT) with a sequential boost (SeqB) following breast-conserving surgery (BCS) in patients with breast cancer. The data showed that both radiotherapy techniques...

Read More

How does daratumumab with lenalidomide and dexamethasone impact the quality of life of patients with multiple myeloma?

How does daratumumab with lenalidomide and dexamethasone impact the quality of life of patients with multiple myeloma?

Posted by on Dec 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the impact of the D-Rd regimen including daratumumab (Darzalex) combined with lenalidomide (Revlimid) and dexamethasone (Decadron) on the quality of life of patients with multiple myeloma (MM) who cannot undergo a transplant. The study showed that patients who received D-Rd reported lower levels of...

Read More

Pembrolizumab plus chemotherapy can delay progression of advanced triple negative breast cancer

Pembrolizumab plus chemotherapy can delay progression of advanced triple negative breast cancer

Posted by on Dec 31, 2020 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of pembrolizumab (Keytruda) plus chemotherapy in patients with inoperable or metastatic triple-negative breast cancer. The data showed that the combination is effective in improving progression-free survival in these patients. Some background Triple-negative breast cancer (TNBC)...

Read More

Adjunct therapy with citicoline improves the symptoms of Parkinson’s disease

Adjunct therapy with citicoline improves the symptoms of Parkinson’s disease

Posted by on Dec 31, 2020 in Parkinson's Disease | 0 comments

In a nutshell This study reviewed the effectiveness of citicoline (CIT; Neurocoline) in improving symptoms of Parkinson’s disease (PD). Researchers suggested that CIT improved the symptoms of these patients. Some background More than 10 million people worldwide live with PD. It affects brain cells which lose their abilities to control body...

Read More

What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?

What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?

Posted by on Dec 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the treatment schedule for panobinostat (Farydak) tablets combines with subcutaneous (injections under the skin) bortezomib (Velcade) and dexamethasone (Ozurdex) tablets in patients with relapsed/refractory (R/R) multiple myeloma (MM). The study found that 20mg of panobinostat should be given twice...

Read More

Evaluating minimally invasive treatment for BPH and the occurrence of ejaculatory dysfunction.

Evaluating minimally invasive treatment for BPH and the occurrence of ejaculatory dysfunction.

Posted by on Dec 31, 2020 in Benign prostatic hyperplasia | 0 comments

In a nutshell This article looked at the use of ejaculatory dysfunction (EjD) as a side effect of minimally invasive procedures for the treatment of benign prostatic hyperplasia (BPH). The authors found that the choice of treatment should be made by doctors together with their patients and should be based on effectiveness and...

Read More

Evaluating long-term outcomes for proton therapy in men with localized prostate cancer.

Evaluating long-term outcomes for proton therapy in men with localized prostate cancer.

Posted by on Dec 31, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined the long-term effectiveness and safety of proton therapy for localized prostate cancer. The data showed that proton therapy has favorable outcomes in these patients. Some background Localized prostate cancer (PCa) is a form of cancer that has not spread beyond the prostate gland. PCa can be treated by...

Read More

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Posted by on Dec 30, 2020 in Melanoma | 0 comments

In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some...

Read More

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Posted by on Dec 30, 2020 in Lung cancer | 0 comments

In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some background...

Read More

What is the optimal timing of surgery for liver metastasis after chemotherapy in patients with colorectal cancer?

What is the optimal timing of surgery for liver metastasis after chemotherapy in patients with colorectal cancer?

Posted by on Dec 30, 2020 in Colorectal cancer | 0 comments

In a nutshell The study evaluated the optimal timing of surgery for colorectal cancer liver metastasis (CRLM) after chemotherapy (CT). The main finding was that surgery within 5 weeks after CT may improve patients' outcomes. Some background Chemotherapy (CT) is used before surgery to remove tumors to reduce tumor size. This is...

Read More